The global market for Idiopathic Pulmonary Fibrosis is estimated at US$4.2 Billion in 2023 and is projected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Pirfenidone Drug segment, which is expected to reach US$4.3 Billion by 2030 with a CAGR of 5.3%. The Nintedanib Drug segment is also set to grow at 6.6% CAGR over the next 7 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $1.3 Billion in 2023, and China, forecasted to grow at an impressive 5.4% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Idiopathic Pulmonary Fibrosis Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Idiopathic Pulmonary Fibrosis Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Idiopathic Pulmonary Fibrosis Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 16 Featured):
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- F. Hoffmann-La Roche AG
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- ProMetic Life Sciences, Inc.
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- F. Hoffmann-La Roche AG
- FibroGen, Inc.
- Galapagos NV
- MediciNova, Inc.
- Merck & Co., Inc.
- Promedior, Inc.
- ProMetic Life Sciences, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 181 |
| Published | April 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 4.2 Billion |
| Forecasted Market Value ( USD | $ 6.1 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
